预测食管癌淋巴结阳性风险的临床列线图
该研究基于美国国家癌症数据库2004-2014年3186例临床T1-3N0M0期接受 upfront 食管切除术的患者,开发并验证了一个预测病理淋巴结阳性(pN+)风险的列线图。多因素分析显示组织学类型、肿瘤分期、肿瘤大小、分级和淋巴血管侵犯与pN+独立相关,列线图预测准确性良好(c-index 0.77)。该工具可用于对临床淋巴结阴性食管癌患者进行风险分层,以优化围术期治疗决策。
要点
- 列线图预测食管癌临床N0患者病理淋巴结阳性风险,c-index为0.77。
- 腺癌相比鳞癌的pN+风险OR为1.75,淋巴血管侵犯OR为4.70。
- 肿瘤大小≥5 cm相比<1 cm的OR为6.02,T3相比T1的OR为2.17。
核心结论
- 基于美国国家癌症数据库开发并验证的列线图可预测临床淋巴结阴性食管癌患者病理淋巴结阳性风险,风险分层有助于改善围术期治疗决策。
研究设计与样本
- 回顾性队列研究,查询美国国家癌症数据库2004至2014年接受 upfront 食管切除术的临床T1-3N0M0期食管癌患者,共3186例。
- 使用多因素logistic回归基于统计显著性和临床重要性选择变量建立风险模型,采用bootstrapping进行验证,并构建列线图展示最终模型。
主要发现
- 3186例患者中,688例(22%)为病理淋巴结阳性(pN+),2498例(78%)为pN0。
- 与pN+相关的变量包括组织学类型(腺癌 vs 鳞癌:OR 1.75)、肿瘤分期(T1为参照,T2:OR 1.90,T3:OR 2.17)、肿瘤大小(<1 cm为参照,1-2 cm:OR 2.25,2-3 cm:OR 3.82,3-4 cm:OR 5.40,4-5 cm:OR 5.66,≥5 cm:OR 6.02)、分级(1为参照,2:OR 2.62,3:OR 4.39,4:OR 4.15,X:OR 1.87)和淋巴血管侵犯(无侵犯为参照,有侵犯:OR 4.70,缺失:OR 1.87),均P < 0.001。
- 列线图预测准确性良好:Brier评分0.14,校准斜率0.97,c-index 0.77。
临床怎么用
- 对于临床T1-3N0M0期拟行 upfront 食管切除术的患者,可使用该列线图评估病理淋巴结阳性风险,辅助决定是否需新辅助治疗或调整围术期管理策略。
局限性
- 研究基于美国国家癌症数据库的回顾性数据,可能存在选择偏倚和未测量混杂因素;列线图的外部泛化性需在其他人群进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We developed and validated a nomogram predicting the likelihood of occult lymph node metastases in surgically resectable esophageal cancers. BACKGROUND: Patients with esophageal cancer with positive lymph nodes benefit from neoadjuvant therapy, but limitations in current clinical staging techniques mean nodal metastases often go undetected preoperatively. METHODS: The National Cancer Database was queried for patients with clinical T1-3N0M0 cancer undergoing upfront esophagectomy from 2004 to 2014. Multivariable logistic regression was used to develop the risk model using both statistical significance and clinical importance criteria for variable selection. Predictive accuracy was assessed and bootstrapping was used for validation. A nomogram was constructed for presentation of the final model. RESULTS: Of 3186 patients, 688 (22%) had pathologic lymph node involvement (pN+) and 2498 (78%) had pN0 status. Variables associated with pN+ status included histology [adenocarcinoma vs squamous: odds ratio (OR) 1.75], tumor stage (T1: reference, T2: OR 1.90, T3: OR 2.17), tumor size (<1 cm: reference, 1-2 cm: OR 2.25, 2-3 cm: OR 3.82, 3-4 cm: OR 5.40, 4-5 cm: OR 5.66, ≥5 cm: OR 6.02), grade (1: reference, 2: OR 2.62, 3: OR 4.39, 4: OR 4.15, X: OR 1.87), and presence of lymphovascular invasion (absent: reference, present: OR 4.70, missing: OR 1.87), all P < 0.001. A nomogram with these variables had good predictive accuracy (Brier score: 0.14, calibration slope: 0.97, c-index: 0.77). CONCLUSIONS: We created a nomogram predicting the likelihood of pathologic lymph node involvement in patients with esophageal cancer who are clinically node negative using a generalizable dataset. Risk stratification with this nomogram could improve delivery of appropriate perioperative care.
引用
- Semenkovich TR, Yan Y, Subramanian M, et al. A Clinical Nomogram for Predicting Node-positive Disease in Esophageal Cancer. Ann Surg. 2021. PMID: 31274650. doi:10.1097/SLA.0000000000003450
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。